Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer
Key facts
- Where
- Busan, Dél-KoreaSee the site
Where in Dél-Korea
- Pusan National University HospitalBusan, Dél-KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pusan National University Hospital
- Trial code
- NCT05517083
- Record updated
- 2025. augusztus 20.
- Original description
The purpose of this study is to evaluate the relevance of intratumoral washing for detection of EGFR mutation (including T790M positivity).Read full original descriptionShow less
Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Advanced Non-small Cell Lung Cancer
The purpose of this study is to evaluate the relevance of intratumoral washing for detection of EGFR mutation (including T790M positivity).
Inclusion: Age ≥ 20 years; Obtained written informed consent; Patients diagnosed with NSCLC by histology or cytology and inoperable stage IV at the time of study enrollment; Patients with the following EGFR gene mutations: E19Del, L858R alone or concurrent rare EGFR gene mutations (T790M, G719X, exon 20 insertion, S768I); Patients previously treated with EGFR-TKIs such as gefitinib, erlotinib, afatinib, dacomitinib as first line therapy; Patients who had shown clinical benefits (CR, PR, SD) from EGFR-TKIs and had been confirmed PD on those therapy according to RECIST v 1.1; Patients who underwent liquid biopsy (plasma) for EGFR mutation at the time of PD on EGFR-TKIs; Patients who plan to undergo tissue biopsy for EGFR mutation at the time of PD on EGFR-TKIs.
Exclusion: Patients who are unable to undergo liquid biopsy (plasma) and tissue biopsy for EGFR mutation based on the investigator's judgement; Patients who withdraw informed consent.